RxDoctor Payments DataLook up a doctor →

Denver Miller, MD

Geriatric Medicine · Sparks, NVNPI 1326059254

Payments from drug & device makers

$6,771in general payments, 2019–2025

Across 414 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$861
  • Astellas Pharma US Inc$564
  • AstraZeneca$434
  • GSK$371
  • Novo Nordisk$284
  • plus $2K from 48 others

What the payments were for

  • Food & beverage$6,67399%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,771 in reported general payments places this provider in the 90th percentile of 36 geriatric medicine providers in Nevada.

See all geriatric medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$297,819
Medicare patients
858
Services billed
3,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$287,843
JardianceEmpagliflozin139$168,628
OzempicSemaglutide124$149,650
XareltoRivaroxaban111$87,066
MyrbetriqMirabegron138$84,259
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$44,581
MounjaroTirzepatide31$37,738
TradjentaLinagliptin36$31,558
JanuviaSitagliptin Phosphate21$30,053
TrulicityDulaglutide18$28,649
FarxigaDapagliflozin Propanediol24$25,401
ProliaDenosumab14$23,253
LinzessLinaclotide22$20,739
Breo ElliptaFluticasone/Vilanterol40$19,759
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen674$19,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$861$287,843465 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Spiriva Respimat, Stiolto Respimat$258$237,530231 claims
Novo NordiskOzempic$284$149,650124 claims
Johnson & JohnsonXarelto$108$87,066111 claims
Astellas Pharma US IncMyrbetriq$564$84,259138 claims
Lilly USA, LLCMounjaro, Trulicity$211$66,38749 claims
GSKTrelegy Ellipta, Breo Ellipta$371$64,340103 claims
MerckJanuvia, Janumet Xr$232$38,97933 claims
AstraZenecaFarxiga, Symbicort$434$33,64855 claims
AmgenProlia$280$23,25314 claims
AbbVieLinzess$1,758$20,73922 claims
NovartisEntresto$27$17,01218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 geriatric medicine providers in Nevada.

Other geriatric medicine in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →